中国肺癌杂志2026，Vol.29Issue(2)：150-158,9.DOI:10.3779/j.issn.1009-3419.2026.101.04
局限期小细胞肺癌治疗新格局:从传统放化疗到精准治疗的新进展
New Landscape in the Treatment of Limited-stage Small Cell Lung Cancer:From Conventional Chemoradiotherapy to Latest Advances in Precision Medicine
摘要
Abstract
Limited-stage small cell lung cancer(LS-SCLC)is a highly aggressive malignancy with a poor progno-sis.For a long time,the standard first-line treatment has been Etoposide plus Platinum-based chemotherapy combined with concurrent thoracic radiotherapy;however,most patients still face recurrence and drug resistance.This article systematically reviews major recent advances in the field,aiming to illustrate the new paradigm shifting from conventional chemoradiotherapy toward precision-integrated therapy.Radiotherapy techniques continue to be optimized,and the value of surgery has been reaf-firmed in rigorously selected early-stage patients;immunotherapy has achieved a milestone breakthrough,with the ADRIATIC trial demonstrating that consolidation therapy with Durvalumab after chemoradiotherapy significantly extends median overall survival(55.9 vs 33.4 months);meanwhile,targeted therapies based on molecular subtyping also show promise.This paper clarifies the optimized directions of multimodal treatment strategies,emphasizes the guiding significance of molecular subtyp-ing and biomarkers in individualized therapy,with the aim of providing reference for clinical practice,offering a framework for future research,and ultimately improving the survival outcomes of LS-SCLC patients as a whole.关键词
肺肿瘤/放化疗/免疫治疗/靶向治疗/分子分型Key words
Lung neoplasms/Chemoradiotherapy/Immunotherapy/Targeted therapy/Molecular subtypes引用本文复制引用
韩敬闻,戴可曜,蒙梓曦,黄俊..局限期小细胞肺癌治疗新格局:从传统放化疗到精准治疗的新进展[J].中国肺癌杂志,2026,29(2):150-158,9.基金项目
This paper was supported by the grant from Science and Technology Innovation Program of Guangdong Province Medical Products Administration(No.2024ZDZ11,to Jun HUANG). 本文受广东省药品监督管理局科技创新计划(No.2024ZDZ11)资助 （No.2024ZDZ11,to Jun HUANG）
